The act of administering alteplase, a tissue plasminogen activator (tPA) often marketed under the trade name Cathflo Activase, directly into a central venous catheter (CVC) is a targeted medical intervention. This procedure aims to dissolve thrombi, or blood clots, that obstruct the catheter’s lumen. For instance, if a CVC is no longer freely infusing fluids or drawing blood, a healthcare provider might carefully inject a small, pre-calculated dose of alteplase into the catheter.
This targeted thrombolysis is crucial for maintaining the functionality of central venous catheters, which are vital for delivering medications, fluids, and nutrition to patients, particularly those undergoing long-term treatments. Its use prevents the need for catheter replacement, minimizing patient discomfort, potential complications associated with new catheter insertions, and overall healthcare costs. The introduction of targeted thrombolysis with alteplase has significantly improved the management of CVC occlusions, leading to better patient outcomes and reduced healthcare burden.
